Palvella Therapeutics Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Palvella Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $229.56. The average 1-year stock price forecast is 118.11% higher than the current stock price, while the lowest is $205 (+94.77%) and the highest is $270 (+156.53%).

Price Target: $229.56 (+118.11%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$205	$229.56	$226	$270
Change	+94.77%	+118.11%	+114.73%	+156.53%

Analyst Ratings

The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	15	15	15	15	16	16
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	15	16	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andrew Fein H.C. Wainwright	H.C. Wainwright	Buy Maintains $270	Buy	Maintains	$270	+156.53%	Jun 4, 2026
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Reiterates $240	Buy	Reiterates	$240	+128.03%	Jun 4, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $227	Buy	Maintains	$227	+115.68%	May 22, 2026
Danielle Brill Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 21, 2026
Trevor Allred Oppenheimer	Oppenheimer	Buy Reiterates $210	Buy	Reiterates	$210	+99.52%	May 21, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

32.47M

EPS This Year

-5.57

from -3.71

EPS Next Year

-6.68

from -5.57

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-
Operating Income	-18.04M	-11.87M	-14.10M	-38.60M	-77.86M
Net Income	-27.55M	18.69M	-17.43M	-41.72M	-79.01M
EPS	-	-	-	-3.71	-5.57
Free Cash Flow	-	-9.96M	-5.43M	-18.63M	-67.84M
No. Analysts	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-3.45
Avg	-5.57
Low	-6.91

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-